These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8885995)

  • 1. Solid-phase synthesis of caged peptides using tyrosine modified with a photocleavable protecting group: application to the synthesis of caged neuropeptide Y.
    Tatsu Y; Shigeri Y; Sogabe S; Yumoto N; Yoshikawa S
    Biochem Biophys Res Commun; 1996 Oct; 227(3):688-93. PubMed ID: 8885995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, receptor binding, and crosslinking of photoactive analogues of neuropeptide Y.
    Beck-Sickinger AG; Wieland HA; Brunner J
    J Recept Signal Transduct Res; 1995; 15(1-4):473-85. PubMed ID: 8903958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability.
    Khan IU; Reppich R; Beck-Sickinger AG
    Biopolymers; 2007; 88(2):182-9. PubMed ID: 17206650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
    Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
    Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caged phospho-amino acid building blocks for solid-phase peptide synthesis.
    Rothman DM; Vazquez ME; Vogel EM; Imperiali B
    J Org Chem; 2003 Aug; 68(17):6795-8. PubMed ID: 12919051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.
    Schober DA; Gackenheimer SL; Heiman ML; Gehlert DR
    J Pharmacol Exp Ther; 2000 Apr; 293(1):275-80. PubMed ID: 10734179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
    Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection.
    Bader R; Bettio A; Beck-Sickinger AG; Zerbe O
    J Mol Biol; 2001 Jan; 305(2):307-29. PubMed ID: 11124908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor.
    Rist B; Wieland HA; Willim KD; Beck-Sickinger AG
    J Pept Sci; 1995; 1(5):341-8. PubMed ID: 9223013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family.
    Cabrele C; Beck-Sickinger AG
    J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of high-potency neuropeptide Y analogues through systematic lactamization.
    Kirby DA; Britton KT; Aubert ML; Rivier JE
    J Med Chem; 1997 Jan; 40(2):210-5. PubMed ID: 9003519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel chemically modified analogues of neuropeptide Y for tumor targeting.
    Zwanziger D; Khan IU; Neundorf I; Sieger S; Lehmann L; Friebe M; Dinkelborg L; Beck-Sickinger AG
    Bioconjug Chem; 2008 Jul; 19(7):1430-8. PubMed ID: 18572959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropeptide Y as a partial agonist of the Y1 receptor.
    Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL
    Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p-Nitrobenzyl side-chain protection for solid-phase synthesis.
    Hocker MD; Caldwell CG; Macsata RW; Lyttle MH
    Pept Res; 1995; 8(6):310-15. PubMed ID: 8838413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strongly altered receptor binding properties in PP and NPY chimeras are accompanied by changes in structure and membrane binding.
    Lerch M; Kamimori H; Folkers G; Aguilar MI; Beck-Sickinger AG; Zerbe O
    Biochemistry; 2005 Jun; 44(25):9255-64. PubMed ID: 15966750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of the human neuropeptide Y Y2-receptor.
    Ingenhoven N; Eckard CP; Gehlert DR; Beck-Sickinger AG
    Biochemistry; 1999 May; 38(21):6897-902. PubMed ID: 10346911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semisynthesis and characterization of the first analogues of pro-neuropeptide y.
    von Eggelkraut-Gottanka R; Machova Z; Grouzmann E; Beck-Sickinger AG
    Chembiochem; 2003 May; 4(5):425-33. PubMed ID: 12740814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review).
    Spinazzi R; Andreis PG; Nussdorfer GG
    Int J Mol Med; 2005 Jan; 15(1):3-13. PubMed ID: 15583821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridone dipeptide backbone scan to elucidate structural properties of a flexible peptide segment.
    Haack M; Enck S; Seger H; Geyer A; Beck-Sickinger AG
    J Am Chem Soc; 2008 Jul; 130(26):8326-36. PubMed ID: 18529062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aza-amino acid scanning of secondary structure suited for solid-phase peptide synthesis with fmoc chemistry and aza-amino acids with heteroatomic side chains.
    Boeglin D; Lubell WD
    J Comb Chem; 2005; 7(6):864-78. PubMed ID: 16283795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.